{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:00Z","timestamp":1790830440847,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13024-018-0259-3","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T08:40:21Z","timestamp":1526892021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse"],"prefix":"10.1186","volume":"13","author":[{"given":"Rebecca","family":"Kusko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dreymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jermaine","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonjeong","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan","family":"Escalante-Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garcia-Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Juin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Burczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Zeskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Laifenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Pouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"259_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M Macdonald","year":"1993","unstructured":"Macdonald M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"259_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","volume":"66","author":"T Foroud","year":"1999","unstructured":"Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington\u2019s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66:52\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR3","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/emboj.2008.133","volume":"27","author":"E Colin","year":"2008","unstructured":"Colin E, Zala D, Liot G, Rangone H, Borrell-Pag\u00e8s M, Li X-J, et al. Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons. EMBO J. 2008;27:2124\u201334.","journal-title":"EMBO J"},{"key":"259_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2217\/fnl.10.41","volume":"5","author":"BR Miller","year":"2010","unstructured":"Miller BR, Bezprozvanny I. Corticostriatal circuit dysfunction in Huntington\u2019s disease: intersection of glutamate, dopamine and calcium. Future Neurol. 2010;5:735\u201356.","journal-title":"Future Neurol"},{"key":"259_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118:127\u201338.","journal-title":"Cell"},{"key":"259_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fnsys.2011.00046","volume":"5","author":"VM Andr\u00e9","year":"2011","unstructured":"Andr\u00e9 VM, Fisher YE, Levine MS. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington\u2019s disease. Front Syst Neurosci. 2011;5:46.","journal-title":"Front Syst Neurosci"},{"key":"259_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","volume":"83","author":"JL Plotkin","year":"2014","unstructured":"Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I, et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease. Neuron. 2014;83:178\u201388.","journal-title":"Neuron"},{"key":"259_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fncel.2016.00037","volume":"10","author":"KQ Nguyen","year":"2016","unstructured":"Nguyen KQ, Rymar VV, Sadikot AF. Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6\/2 mouse model of Huntington\u2019s disease. Front Cell Neurosci. 2016;10:37.","journal-title":"Front Cell Neurosci"},{"key":"259_CR9","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1073\/pnas.120166397","volume":"97","author":"JA Bibb","year":"2000","unstructured":"Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington\u2019s disease mice. Proc Natl Acad Sci U S A. 2000;97:6809\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG de Yebenes","year":"2011","unstructured":"de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:1049\u201357.","journal-title":"Lancet Neurol"},{"key":"259_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"The Huntington Study Group HART Investigators","year":"2013","unstructured":"The Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28:1407\u201315.","journal-title":"Mov Disord"},{"key":"259_CR12","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","volume":"232","author":"K Sahlholm","year":"2015","unstructured":"Sahlholm K, Sijbesma JWA, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, et al. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology. 2015;232:3443\u201353.","journal-title":"Psychopharmacology"},{"key":"259_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejphar.2012.10.039","volume":"698","author":"H Ponten","year":"2013","unstructured":"Ponten H, Kullingsj\u00f6 J, Sonesson C, Waters S, Waters N, Tedroff J. The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol. 2013;698:278\u201385.","journal-title":"Eur J Pharmacol"},{"key":"259_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","volume":"628","author":"T Dyhring","year":"2010","unstructured":"Dyhring T, Nielsen E\u00d8, Sonesson C, Pettersson F, Karlsson J, Svensson P, et al. The dopaminergic stabilizers pridopidine (ACR16) and (\u2212)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010;628:19\u201326.","journal-title":"Eur J Pharmacol"},{"key":"259_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"D Ryskamp","year":"2017","unstructured":"Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97:46\u201359.","journal-title":"Neurobiol Dis"},{"key":"259_CR16","doi-asserted-by":"crossref","unstructured":"Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J Cell Mol Med. 2015;19(11):2540\u2013548.","DOI":"10.1111\/jcmm.12604"},{"key":"259_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"CA Altar","year":"1997","unstructured":"Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389:856\u201360.","journal-title":"Nature"},{"key":"259_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12:1555\u201367.","journal-title":"Hum Mol Genet"},{"key":"259_CR19","doi-asserted-by":"publisher","unstructured":"Garcia-Miralles M, Geva M, Tan JY, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2(23):e95665. \n                    https:\/\/doi.org\/10.1172\/jci.insight.95665\n                    \n                  .","DOI":"10.1172\/jci.insight.95665"},{"key":"259_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"259_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"259_CR22","doi-asserted-by":"crossref","unstructured":"Su Z, \u0141abaj PP, Li S, Thierry-Mieg J, Thierry-Mieg D, et al. Seqc\/Maqc-Iii Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the sequencing quality control consortium. Nat Biotechnol 2014;32:903\u2013914.","DOI":"10.1038\/nbt.2957"},{"key":"259_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"259_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"259_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1471-4159.2008.05489.x","volume":"106","author":"H Sato","year":"2008","unstructured":"Sato H, Horikawa Y, Iizuka K, Sakurai N, Tanaka T, Shihara N, et al. Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J Neurochem. 2008;106:805\u201314.","journal-title":"J Neurochem"},{"key":"259_CR26","doi-asserted-by":"publisher","first-page":"e5292","DOI":"10.1371\/journal.pone.0005292","volume":"4","author":"O Gokce","year":"2009","unstructured":"Gokce O, Runne H, Kuhn A, Luthi-Carter R. Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One. 2009;4:e5292.","journal-title":"PLoS One"},{"key":"259_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2174\/187152710793361496","volume":"9","author":"JL Cadet","year":"2010","unstructured":"Cadet JL, Jayanthi S, McCoy MT, Beauvais G, Cai NS. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration. CNS Neurol Disord Drug Targets. 2010;9:526\u201338.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"259_CR28","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/nbt1239","volume":"24","author":"SL Maqc Consortium","year":"2006","unstructured":"Maqc Consortium SL, Shi L, Reid LH, Jones WD, Shippy R, et al. The MicroArray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24:1151\u201361.","journal-title":"Nat Biotechnol"},{"key":"259_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-S18-S1","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:1\u201314.","journal-title":"BMC Bioinformatics"},{"key":"259_CR30","doi-asserted-by":"crossref","unstructured":"Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975\u2013987.","DOI":"10.1093\/hmg\/ddw238"},{"key":"259_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1210\/jc.2008-2543","volume":"94","author":"NA Aziz","year":"2009","unstructured":"Aziz NA, Pijl H, Fr\u00f6lich M, van der Graaf AWM, Roelfsema F, Roos RAC. Increased hypothalamic-pituitary-adrenal axis activity in Huntington\u2019s disease. J Clin Endocrinol Metab. 2009;94:1223\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"259_CR32","doi-asserted-by":"publisher","first-page":"e0144398","DOI":"10.1371\/journal.pone.0144398","volume":"10","author":"X Dong","year":"2015","unstructured":"Dong X, Tsuji J, Labadorf A, Roussos P, Chen J-F, Myers RH, et al. The role of H3K4me3 in transcriptional regulation is altered in Huntington\u2019s disease. PLoS One. 2015;10:e0144398.","journal-title":"PLoS One"},{"key":"259_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nbd.2009.07.014","volume":"36","author":"Y-S Choi","year":"2009","unstructured":"Choi Y-S, Lee B, Cho H-Y, Reyes IB, Pu X-A, Saido TC, et al. CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington\u2019s disease. Neurobiol Dis. 2009;36:259\u201368.","journal-title":"Neurobiol Dis"},{"key":"259_CR34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1471-4159.2003.01610.x","volume":"84","author":"J-M Taymans","year":"2003","unstructured":"Taymans J-M, Leysen JE, Langlois X. Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem. 2003;84:1118\u201327.","journal-title":"J Neurochem"},{"key":"259_CR35","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci. 2010;30:14708\u201318.","journal-title":"J Neurosci"},{"key":"259_CR36","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1093\/hmg\/ddt667","volume":"23","author":"M Maheshwari","year":"2014","unstructured":"Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y, et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington\u2019s disease. Hum Mol Genet. 2014;23:2737\u201351.","journal-title":"Hum Mol Genet"},{"key":"259_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","volume":"644","author":"H Ponten","year":"2010","unstructured":"Ponten H, Kullingsj\u00f6 J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010;644:88\u201395.","journal-title":"Eur J Pharmacol"},{"key":"259_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.tips.2016.07.003","volume":"37","author":"T Nagai","year":"2016","unstructured":"Nagai T, Yoshimoto J, Kannon T, Kuroda K, Kaibuchi K. Phosphorylation signals in striatal medium spiny neurons. Trends Pharmacol Sci. 2016;37:858\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"259_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/hmg\/ddg046","volume":"12","author":"S Gines","year":"2003","unstructured":"Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice. Hum Mol Genet. 2003;12:497\u2013508.","journal-title":"Hum Mol Genet"},{"key":"259_CR40","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/MCB.01434-12","volume":"33","author":"J-T Lin","year":"2013","unstructured":"Lin J-T, Chang W-C, Chen H-M, Lai H-L, Chen C-Y, Tao M-H, et al. Regulation of feedback between protein kinase a and the proteasome system worsens Huntington\u2019s disease. Mol Cell Biol. 2013;33:1073\u201384.","journal-title":"Mol Cell Biol"},{"key":"259_CR41","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1172\/JCI59426","volume":"122","author":"G Porras","year":"2012","unstructured":"Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, et al. PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest. 2012;122:3977\u201389.","journal-title":"J Clin Invest"},{"key":"259_CR42","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1074\/jbc.M113.513945","volume":"289","author":"MP Parsons","year":"2014","unstructured":"Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, et al. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by huntingtin. J Biol Chem. 2014;289:3518\u201328.","journal-title":"J Biol Chem"},{"key":"259_CR43","doi-asserted-by":"publisher","first-page":"15778","DOI":"10.1074\/jbc.M611485200","volume":"282","author":"J Zhang","year":"2007","unstructured":"Zhang J, Vinuela A, Neely MH, Hallett PJ, Grant SGN, Miller GM, et al. Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem. 2007;282:15778\u201389.","journal-title":"J Biol Chem"},{"key":"259_CR44","doi-asserted-by":"publisher","first-page":"24713","DOI":"10.1074\/jbc.M103501200","volume":"276","author":"Y Sun","year":"2001","unstructured":"Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001;276:24713\u20138.","journal-title":"J Biol Chem"},{"key":"259_CR45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.cell.2014.03.058","volume":"157","author":"I Spiegel","year":"2014","unstructured":"Spiegel I, Mardinly A, Gabel H, Bazinet J, Couch C, Tzeng C, et al. Npas4 regulates excitatory-inhibitory balance within neural circuits through cell type-specific gene programs. Cell. 2014;157:1216\u201329.","journal-title":"Cell"},{"issue":"Pt 3","key":"259_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1042\/bj3090837","volume":"309","author":"D Eggerickx","year":"1995","unstructured":"Eggerickx D, Denef JF, Labbe O, Hayashi Y, Refetoff S, Vassart G, et al. Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem J. 1995;309(Pt 3):837\u201343.","journal-title":"Biochem J"},{"key":"259_CR47","doi-asserted-by":"publisher","first-page":"e4704","DOI":"10.1371\/journal.pone.0004704","volume":"4","author":"O Valverde","year":"2009","unstructured":"Valverde O, C\u00e9l\u00e9rier E, Baranyi M, Vanderhaeghen P, Maldonado R, Sperlagh B, et al. GPR3 receptor, a novel actor in the emotional-like responses. PLoS One. 2009;4:e4704.","journal-title":"PLoS One"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-018-0259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-018-0259-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-018-0259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T19:05:24Z","timestamp":1558379124000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-018-0259-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s13024-018-0259-3","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Information for all the co-authors is listed in the title page.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"All mouse experiments were performed with the approval of and in accordance with the Institutional Animal Care and Use Committee at the Biomedical Sciences Institute at the Agency for Science, Technology and Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RK, JR, YC, REC, BZ are employees of Immuneering Corporation. JD, MEB, DL, MG, IG, and MRH are employees of Teva Pharmaceutical. Teva Pharmaceuticals played no role in the treatment or testing of animals, or the collection, or analysis of the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"25"}}